Levothyroxine Sodium 300 mcg Tablets Recalled for Subpotency
Accord Healthcare is recalling Levothyroxine Sodium Tablets 300 mcg (90-tablet bottles) nationwide due to subpotency. The affected lot is D2401522 with expiration date 06/2026.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for subpotency (reduced therapeutic efficacy) with no reported illnesses or adverse events. The source text states no reported illnesses or hospitalizations, and subpotency represents a loss of efficacy rather than an acute safety hazard, consistent with a Moderate severity rating.
Plain-English summary
Accord Healthcare, Inc. is voluntarily recalling Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg) in 90-tablet bottles due to subpotency. The recalled lot is D2401522 with an expiration date of 06/2026. Approximately 6,432 bottles have been distributed nationwide. The product is manufactured by Intas Pharmaceuticals Limited in India and distributed in the United States.
Levothyroxine Sodium is an oral prescription medication used to treat thyroid conditions. If the tablets are subpotent, patients may not receive the full intended therapeutic dose. Consumers who have this medication should not stop taking it without consulting their healthcare provider, as abrupt discontinuation could affect their thyroid treatment.
Patients with this lot should contact their pharmacy or healthcare provider immediately. Healthcare providers and pharmacies should verify if they have received product from lot D2401522 and quarantine it. The FDA has classified this as a Class II recall. The recall was initiated on June 8, 2026, and the firm notified the FDA by letter.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Hazard
- subpotency
- reduced-efficacy
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # D2401522
- Exp Date: 06/2026.
UPCs (12)
- 0316729447157
- 0316729449151
- 0316729452151
- 0316729454155
- 0316729453158
- 0316729448154
- 0316729451154
- 0316729457156
- 0316729450157
- 0316729456159
- 0316729458153
- 0316729455152
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
FDA (Drugs) · 2025-03-26
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium tablets recalled for impurity specification failure
FDA (Drugs) · 2025-01-08
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Sterile Solution Lacks Assurance of Sterility
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Applicators Recalled for Lack of Sterile Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Antiseptic Applicators recalled for lack of sterility assurance
FDA (Drugs) · 2026-07-08